为儿科和新生儿药物管理临床决策支持系统 (MACDSS) 开发最低数据集,映射到FHIR:混合方法研究综合
Somaye Norouzi1,2, Jila Agah3, Zahra Sarkohi4
1Non-Communicable Diseases Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran.
BMC medical informatics and decision making
|February 21, 2026
概括
开发一个标准化的最小数据集 (MDS) 用于药物在儿科的管理提高了安全性. 这个基本框架确保了数据的一致性和与电子健康记录 (EHR) 的互操作性.
科学领域:
- 医疗信息学 医疗信息学
- 儿科护理 儿科护理
- 临床决策支持系统 临床决策支持系统
背景情况:
- 儿科药物管理复杂且安全至关重要,现有的临床决策支持系统 (CDSS) 缺乏在药物管理阶段为护士提供支持.
- 目前的CDSS通常具有异质的数据结构,阻碍了临床实践中的互操作性,一致性和可扩展性.
- 标准化的最低数据集 (MDS) 对于开发适合儿科和新生儿护理的有效药物管理CDSS (MACDSS) 是至关重要的.
研究的目的:
- 为了建立一个标准化的最小数据集 (MDS) 用于药物管理在儿科和新生儿护理.
- 确保数据的一致性,互操作性,并与HL7快速医疗互操作性资源 (FHIR) 等国际标准保持一致.
- 增强弱势儿科和新生儿群体的药物安全性.
主要方法:
- 一种研究综合方法,结合了定性研究和系统文献审查.
- 定性阶段确定了护士的需求和卫生信息技术采用的障碍.
- 在四个数据库中进行系统的文献审查,提取数据元素,用定性数据进行合成,并由专家小组改进.
主要成果:
- 确定了用于药物管理的33个基本数据元素,分为个人 (7),诊断 (4) 和药物 (22).
- 将已识别的数据元素映射到HL7快速医疗互操作资源 (FHIR) 标准中,其中14个元素与FHIR扩展相关.
- 由专家小组验证,确保相关性,准确性和互操作性,以提高药物安全性.
结论:
- 一个由33个元素组成的MDS,映射到FHIR,是通过综合研究方法开发的.
- 该框架为儿童和新生儿医学中更安全的药物管理提供了基础.
- 该研究指导了未来的健康信息系统设计和研究,以提高患者安全.
相关概念视频
Drug Dosing: Infants and Children
371
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
371
Pharmacokinetics in Pediatric Patients: Drug Excretion
302
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
302
Dosage Regimens: Partial Pharmacokinetic Parameters
205
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
205
Dosage Regimens: Designs and Approaches
367
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
367
Dosage Regimen Designs: Nomograms and Tabulations
239
Nomograms and tabulations are vital tools used by clinicians to design accurate and individualized dosage regimens. These instruments provide a straightforward method for adjusting dosages based on individual patient characteristics, including age, weight, and physiological condition. The foundation of a drug's nomogram is population pharmacokinetic data collected and analyzed using specific models. This data simplifies complex equations, presenting them diagrammatically or tabularly for easy...
239
Pharmacokinetics in Pediatric Patients: Drug Distribution
356
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
356


